Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas

Fabio M. Iwamoto; Andreas F. Hottinger; Sasan Karimi; Elyn Riedel; Jocelynn Dantis; Maryam Jahdi; Katherine S. Panageas; Andrew B. Lassman; Lauren E. Abrey; Martin Fleisher; Lisa M. Deangelis; Eric C. Holland; Adília Hormigo

doi:10.1007/s11060-011-0628-z

Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas

Fabio M. Iwamoto, Andreas F. Hottinger, Sasan Karimi, Elyn Riedel, Jocelynn Dantis, Maryam Jahdi, Katherine S. Panageas, Andrew B. Lassman, Lauren E. Abrey, Martin Fleisher, Lisa M. Deangelis, Eric C. Holland, Adília Hormigo

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

The objective of this study was to evaluate if longitudinal measurements of serum matrix metalloproteinase-9 (MMP-9) correlated with disease status or survival in adults with gliomas. Serum samples were collected prospectively and concurrently with MRI scans at multiple time points during the course of the disease. MMP-9 levels were determined by ELISA and correlated with radiographic disease status and survival. Forty-one patients with low-grade gliomas, 105 with anaplastic gliomas, and 197 with glioblastoma enrolled in this study from August 2002 to September 2008. A total of 1,684 serum samples (97.1% of all MMP-9 samples) had a matching MRI scan. No statistically significant association was observed between levels of serum MMP-9 and radiographic disease status in low-grade gliomas (P = 0.98), anaplastic gliomas (P = 0.39) or glioblastomas (P = 0.33). Among patients with glioblastoma, longitudinal increases in MMP-9 had a weak association with shorter survival (HR = 1.1 per each doubling in MMP-9 levels, 95% CI, 1.0-1.3, P = 0.04) but they were not independently associated with survival when adjusted for age, extent of resection, and performance status. Changes in serum MMP-9 were not associated with survival in the anaplastic glioma cohort. Serum MMP-9 showed no utility in determining glioma disease status and was not a clinically relevant prognostic marker of survival.

Original language	English (US)
Pages (from-to)	607-612
Number of pages	6
Journal	Journal of Neuro-Oncology
Volume	105
Issue number	3
DOIs	https://doi.org/10.1007/s11060-011-0628-z
State	Published - Dec 2011
Externally published	Yes

Keywords

Glioblastoma
Glioma
Matrix metalloproteinase-9
Serum marker

ASJC Scopus subject areas

Oncology
Neurology
Clinical Neurology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11060-011-0628-z

Cite this

Iwamoto, F. M., Hottinger, A. F., Karimi, S., Riedel, E., Dantis, J., Jahdi, M., Panageas, K. S., Lassman, A. B., Abrey, L. E., Fleisher, M., Deangelis, L. M., Holland, E. C., & Hormigo, A. (2011). Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. Journal of Neuro-Oncology, 105(3), 607-612. https://doi.org/10.1007/s11060-011-0628-z

@article{758184de86314fa99add025b23c94122,

title = "Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas",

abstract = "The objective of this study was to evaluate if longitudinal measurements of serum matrix metalloproteinase-9 (MMP-9) correlated with disease status or survival in adults with gliomas. Serum samples were collected prospectively and concurrently with MRI scans at multiple time points during the course of the disease. MMP-9 levels were determined by ELISA and correlated with radiographic disease status and survival. Forty-one patients with low-grade gliomas, 105 with anaplastic gliomas, and 197 with glioblastoma enrolled in this study from August 2002 to September 2008. A total of 1,684 serum samples (97.1% of all MMP-9 samples) had a matching MRI scan. No statistically significant association was observed between levels of serum MMP-9 and radiographic disease status in low-grade gliomas (P = 0.98), anaplastic gliomas (P = 0.39) or glioblastomas (P = 0.33). Among patients with glioblastoma, longitudinal increases in MMP-9 had a weak association with shorter survival (HR = 1.1 per each doubling in MMP-9 levels, 95% CI, 1.0-1.3, P = 0.04) but they were not independently associated with survival when adjusted for age, extent of resection, and performance status. Changes in serum MMP-9 were not associated with survival in the anaplastic glioma cohort. Serum MMP-9 showed no utility in determining glioma disease status and was not a clinically relevant prognostic marker of survival.",

keywords = "Glioblastoma, Glioma, Matrix metalloproteinase-9, Serum marker",

author = "Iwamoto, {Fabio M.} and Hottinger, {Andreas F.} and Sasan Karimi and Elyn Riedel and Jocelynn Dantis and Maryam Jahdi and Panageas, {Katherine S.} and Lassman, {Andrew B.} and Abrey, {Lauren E.} and Martin Fleisher and Deangelis, {Lisa M.} and Holland, {Eric C.} and Ad{\'i}lia Hormigo",

note = "Funding Information: F. M. Iwamoto Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Funding Information: Acknowledgments Grant support to Ad{\'i}lia Hormigo from the Society for Memorial Sloan-Kettering Cancer Center.",

year = "2011",

month = dec,

doi = "10.1007/s11060-011-0628-z",

language = "English (US)",

volume = "105",

pages = "607--612",

journal = "Journal of Neuro-Oncology",

issn = "0167-594X",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas

AU - Iwamoto, Fabio M.

AU - Hottinger, Andreas F.

AU - Karimi, Sasan

AU - Riedel, Elyn

AU - Dantis, Jocelynn

AU - Jahdi, Maryam

AU - Panageas, Katherine S.

AU - Lassman, Andrew B.

AU - Abrey, Lauren E.

AU - Fleisher, Martin

AU - Deangelis, Lisa M.

AU - Holland, Eric C.

AU - Hormigo, Adília

N1 - Funding Information: F. M. Iwamoto Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Funding Information: Acknowledgments Grant support to Adília Hormigo from the Society for Memorial Sloan-Kettering Cancer Center.

PY - 2011/12

Y1 - 2011/12

N2 - The objective of this study was to evaluate if longitudinal measurements of serum matrix metalloproteinase-9 (MMP-9) correlated with disease status or survival in adults with gliomas. Serum samples were collected prospectively and concurrently with MRI scans at multiple time points during the course of the disease. MMP-9 levels were determined by ELISA and correlated with radiographic disease status and survival. Forty-one patients with low-grade gliomas, 105 with anaplastic gliomas, and 197 with glioblastoma enrolled in this study from August 2002 to September 2008. A total of 1,684 serum samples (97.1% of all MMP-9 samples) had a matching MRI scan. No statistically significant association was observed between levels of serum MMP-9 and radiographic disease status in low-grade gliomas (P = 0.98), anaplastic gliomas (P = 0.39) or glioblastomas (P = 0.33). Among patients with glioblastoma, longitudinal increases in MMP-9 had a weak association with shorter survival (HR = 1.1 per each doubling in MMP-9 levels, 95% CI, 1.0-1.3, P = 0.04) but they were not independently associated with survival when adjusted for age, extent of resection, and performance status. Changes in serum MMP-9 were not associated with survival in the anaplastic glioma cohort. Serum MMP-9 showed no utility in determining glioma disease status and was not a clinically relevant prognostic marker of survival.

AB - The objective of this study was to evaluate if longitudinal measurements of serum matrix metalloproteinase-9 (MMP-9) correlated with disease status or survival in adults with gliomas. Serum samples were collected prospectively and concurrently with MRI scans at multiple time points during the course of the disease. MMP-9 levels were determined by ELISA and correlated with radiographic disease status and survival. Forty-one patients with low-grade gliomas, 105 with anaplastic gliomas, and 197 with glioblastoma enrolled in this study from August 2002 to September 2008. A total of 1,684 serum samples (97.1% of all MMP-9 samples) had a matching MRI scan. No statistically significant association was observed between levels of serum MMP-9 and radiographic disease status in low-grade gliomas (P = 0.98), anaplastic gliomas (P = 0.39) or glioblastomas (P = 0.33). Among patients with glioblastoma, longitudinal increases in MMP-9 had a weak association with shorter survival (HR = 1.1 per each doubling in MMP-9 levels, 95% CI, 1.0-1.3, P = 0.04) but they were not independently associated with survival when adjusted for age, extent of resection, and performance status. Changes in serum MMP-9 were not associated with survival in the anaplastic glioma cohort. Serum MMP-9 showed no utility in determining glioma disease status and was not a clinically relevant prognostic marker of survival.

KW - Glioblastoma

KW - Glioma

KW - Matrix metalloproteinase-9

KW - Serum marker

UR - http://www.scopus.com/inward/record.url?scp=82955203351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955203351&partnerID=8YFLogxK

U2 - 10.1007/s11060-011-0628-z

DO - 10.1007/s11060-011-0628-z

M3 - Article

C2 - 21710351

AN - SCOPUS:82955203351

SN - 0167-594X

VL - 105

SP - 607

EP - 612

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

IS - 3

ER -

Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this